Agilent Technologies to License Incyte Genomics' Gene Patent Portfolio and cDNA Clone Sets for the Development of Microarray Systems Agreement Enables Agilent to Use Incyte's Gene Sequences to Produce Gene Expression Microarrays Palo Alto, CA, January 8, 2001 -- Agilent Technologies Inc. (NYSE: A), a leading provider of innovative technologies for communications and life sciences, and Incyte Genomics Inc. (Nasdaq: INCY), the leading genomic information company, today announced that they have entered into a multi-million dollar non-exclusive licensing agreement for the development and commercialization of gene expression arrays using Incyte's sequence-verified, non-redundant cDNA clone sets. The licensing agreement will allow Agilent to use cDNA clones, isolated and sequenced by Incyte, to develop comprehensive human and animal microarrays to identify critical genes involved in various biological processes. In particular, researchers in pharmaceutical and biotechnology companies can use these arrays to identify new potential drug targets. Incyte will receive royalties on sales of Agilent microarrays developed using Incyte's clone technology. Further financial details of the agreement were not disclosed. The licensing agreement allows Agilent to use Incyte's sequence-verified cDNA clones to develop high quality arrays to perform sensitive and quantitative gene expression analysis. With these arrays, researchers will be able to characterize expression of many thousands of genes at one time and identify gene activity during important biological processes, such as during disease progression and pathology, human growth and development, and in response to drugs or toxins. Researchers using Agilent microarrays will be able to access Incyte's LifeSeq Gene-by-Gene Web site to purchase additional gene sequence information and clones related to Incyte's proprietary genes for use in conducting further research. Genes responsible for these processes often provide the basis for diagnostic markers and can be excellent targets for drug therapies. "We are pleased to be working with Incyte to develop these important cDNA clone arrays which compliment Agilent's custom oligo microarray program," said Barney Saunders, vice president and general manager of Agilent's Bio-Research Solutions Unit. "Now researchers in pharmaceutical and biotechnology companies will have simple easy access to powerful new cDNA microarrays to identify new drug targets that could potentially bring cures or relief for a wide variety of human diseases and conditions, such as cancer, heart disease, Alzheimer's and diabetes. About Agilent Technologies in Gene Expression Agilent Technologies is a leading provider of solutions, including consulting services, informatics software and tools for gene expression analysis, a fast-growing field of study that allows researchers to identify key gene transcriptional regulatory events or pathways associated with diseases or biologies. Researchers can select from pre-fabricated cDNA arrays or do rapid, iterative, hypothesis-driven research using custom-designed microarrays developed by Agilent to be delivered within days. Agilent is also a leading manufacturer of high-quality bioanalyzers and microarray scanners. Agilent supports the collaborative research efforts by the National Human Genome Research Institute (NHGRI) and others to analyze genome-wide patterns of mRNA expression, and is actively driving open data standards for gene expression research in alliance with Rosetta Inpharmatics Inc. About Incyte Genomics, Inc. Incyte Genomics, Inc. is the leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's Web site at www.incyte.com. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a diversified technology company with approximately 47,000 employees serving customers in more than 120 countries. Agilent is a global leader in designing and manufacturing test, measurement and monitoring instruments, systems and solutions, and semiconductor and optical components. In fiscal year 2000, Agilent had net revenue of $10.8 billion. The company serves markets that include communications, electronics, life sciences and healthcare. Information about Agilent Technologies can be found on the Web at http://www.agilent.com. Except for the historical information contained herein, the matters set forth in this press release, including statements as to Incyte's ability to obtain potential revenues received on royalties from sales of microarrays, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, the ability to meet goals of the collaboration; Incyte's ability to enforce drug target patents and changes in laws as they affect such patents; alternative technological advances and competition; and other risks detailed from time to time in Incyte's and Agilent's SEC reports, including their respective Quarterly Reports on Form 10-Q for the Incyte quarter ended September 30, 2000 and the Agilent quarter ended July 31, 2000. Incyte and Agilent disclaim any intent or obligation to update these forward-looking statements.